Mr Robeert Michael Howe, LCSW | |
131 Nw Hawthorne Ave Ste 207, Bend, OR 97703-2958 | |
(413) 064-4465 | |
(541) 550-2011 |
Full Name | Mr Robeert Michael Howe |
---|---|
Gender | Male |
Speciality | Counselor - Addiction (substance Use Disorder) |
Location | 131 Nw Hawthorne Ave Ste 207, Bend, Oregon |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1063903326 | NPI | - | NPPES |
18-R-01 | Other | OR | ACCBO |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | (* (Not Available)) | Secondary |
101YA0400X | Counselor - Addiction (substance Use Disorder) | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Robeert Michael Howe, LCSW 131 Nw Hawthorne Ave Ste 207, Bend, OR 97703-2958 Ph: (541) 306-4446 | Mr Robeert Michael Howe, LCSW 131 Nw Hawthorne Ave Ste 207, Bend, OR 97703-2958 Ph: (413) 064-4465 |
News Archive
Politics continue to swirl around health overhaul and deficit reduction issues. A new Bloomberg poll, for instance, indicates that the public wants the deficit addressed, but still wants Congress to stay away from Medicare, Medicaid and other entitlement programs. Meanwhile, a GOP senator targets the catch-all spending bill to fund the government as a "trojan horse" to fund the health overhaul. Off the hill, groups are paying particular attention to the words used in discussing health policy issues.
Investigational drug Abraxane™ (albumin nanoparticle paclitaxel), administered weekly without steroid premedication, is active and well tolerated in women with metastatic breast cancer whose disease had progressed while they were treated with paclitaxel (Taxol®) and/or docetaxel (Taxotere®).
Retrophin, Inc. today announced that it has signed an agreement with Novartis Pharma AG for an exclusive U.S. license for Syntocinon Nasal Spray, the intranasal formulation of a synthetic version of the naturally occurring peptide hormone oxytocin, for an upfront payment of $5.0 million plus milestone payments and royalties.
Is anyone listening? As this debate rages on about medical reform, patient safety organizations, those of us at the front each and every day, we do not hear about what is happening to the people from the senseless health care devastation throughout our country right now.
› Verified 9 days ago